Xeris Pharmaceuticals Inc XERS

$16.99 +0.19 (1.13%)

Valuation

Market cap
3,069,360,000
Revenue TTM
$291,850,000
Net income TTM
$550,000
P/E (trailing)
128.46
P/E (forward)
111.33
Profit margin
0.19%
Debt to equity
3.89

Trading

Volume
2,761,800
Avg volume
3,225,004
Day's range
$16.72 – $17.28
Shares out
182,700,000
Stochastic %K
92%
Beta
0.61
Analysts
Strong Buy
Price target
$17.14

Price

Company profile

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary p...

Show more

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
844 445 5704
Website
https://www.xerispharma.com
Address
1375 West Fulton Street, Suite 1300, Chicago, United States

Latest news

Stocktwits

Bullisch_150 Nov 19, 8:44 AM
$XERS remember: end november 50$ for a share buyout
0 replies
PatFB Nov 19, 1:48 AM
$XERS interesting tape lately. Does the market know something?
0 replies
Northwoodspeculator Nov 19, 1:31 AM
$XERS nice after hours let’s start the big move to take care of these shorts
0 replies
marpious Nov 18, 10:45 PM
$XERS LOOKING GOOD!!!! Heck ya!
0 replies
LionFox Nov 18, 10:15 PM
$XERS I remember the days where I DREADED to look at my Fidelity account. Different story now. Patience pays.
1 replies
PJACOB01 Nov 18, 7:38 PM
$XERS stockinvest: The price is near the upper part of a rising short-term trend. A pullback within the channel is possible, while a break above $16.97 would suggest a faster rise. The channel is very wide, so the range of possible outcomes is broad. The recent negative signals warn of weakness within this rising channel; they do not, by themselves, mean its direction has reversed. On the 12-month chart, the price is above the channel ceiling at $12.23, a sign of strength that still needs to hold. Neither the 12- nor the 18-month technical assessment gives a clear positive or negative signal. If the current short-term trend holds, the model projects a rise of 67.68% over the next three months, with a 90% probability range of $20.93 to $28.46 at the end of that period.
0 replies
nomoney82742 Nov 18, 7:20 PM
$XERS damn i cant believe i sold this at 3$ 🤣
1 replies
StarF Nov 18, 7:06 PM
$XERS 17 was a hard age..
1 replies